Physician profile
Reece Clark
NPI 1528622123
$3,358.79
in general payments reported to CMS, 2019-2025
18 companies · $551 in 2025
The $551 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $145 · 2024: $2,662 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859 · Education: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.79 |
| Education | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,500.00 | 2024 | |
| Pfizer INC. | $405.46 | 2023-2025 | |
| Exeltis, USA INC. | $371.09 | 2024-2025 | Slynd |
| Novo Nordisk INC | $233.12 | 2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $162.49 | 2023-2025 | Airsupra |
| Amgen INC. | $149.20 | 2024-2025 | Evenity, Prolia, Repatha |
| Sumitomo Pharma America, INC. | $96.01 | 2024-2025 | Gemtesa, Myfembree |
| Abbvie INC. | $74.91 | 2024-2025 | |
| Lilly USA, LLC | $72.78 | 2024-2025 | Zepbound, Mounjaro |
| Biogen, INC. | $60.13 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $51.46 | 2024-2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $47.23 | 2023-2024 | Gvoke Hypopen |
| Coopersurgical, INC. | $34.39 | 2024-2025 | Paragard T 380a |
| Seqirus USA INC | $30.15 | 2024 | Flucelvax, Fluad |
| Dexcom, INC. | $20.94 | 2024 | Dexcom G6 Transmitter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.83 | 2023 | Belsomra |
| Axsome Therapeutics, INC. | $16.80 | 2024 | Auvelity |
| Ibsa Pharma INC. | $12.80 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reece Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.